ITBT & AI Drug Discovery Forum: Reshaping the Future R&D Paradigm and Market Landscape of Pharmaceuticals

Mar 27, 2023 18:00 CST Updated 18:00

ITBT is a new concept derived from artificial intelligence and big data, representing an organic integration of Information Technology (IT) in computational science and Biotechnology (BT) in life sciences, with a focus on biopharmaceutical development driven by big data algorithms. ITBT has become one of the hottest fields in biopharmaceuticals. The convergence of IT and BT technologies has unleashed infinite possibilities, among which AI-driven drug discovery represents the most significant and extensive intersection of IT and BT. By leveraging biological data processed through information technology, this approach accelerates drug R&D while enhancing drug quality, with the ultimate goal of delivering high-quality novel drugs and vaccines in a shorter timeframe.

Despite2022 was widely recognized as a "winter" for the pharmaceutical industry, yet capital interest in AI-driven drug discovery remained undiminished. Throughout 2022, there were 144 financing deals related to AI-enabled drug R&D, totaling $6.202 billion. This represents a significant increase from 2021, which saw 77 deals totaling $4.5 billion. Unlike previous years, when AI applications in small-molecule drug development dominated the landscape, 2022 marked a shift as investors began to place greater emphasis on startups leveraging AI for biologic macromolecule therapeutics.

The heat has surprisingly not subsided, leaving the currentProminent challenges in the ITBT and AI-driven drug discovery sector have come to light. The scarcity of high-quality data, the lack of interpretability in purely data-driven AI models, and the difficulty in generalizing AI-assisted drug discovery remain significant hurdles. Although the prospects for AI in pharmaceuticals are widely regarded as promising, no AI-developed drug has successfully reached the market globally to date. Most AI-focused pharmaceutical companies remain in the exploratory research phase, making short-term commercial viability difficult to achieve.

To present a clearer blueprint for industrial development and promoteFurther Development of the ITBT Industry, The 7th Future HealthcareThe Top 100 Conference is hereby hosted, with support from Source Code Capital.ITBT & AI Drug Discovery Forum，AroundA Deep Dive into AI Drug Discovery and Hot Topics in Cross-Disciplinary Fields from the ITBT Perspective, Featuring Shares and Dialogues with Leading Enterprises and Senior Investors,Seeking to Identify the Key to Industrial Breakthroughs.

主k定稿.jpg

I.Forum Highlights:

(1)Innovative Breakthroughs:The “Perfect Storm” Behind the ITBT Boom

With the enhancement of computational power in China’s computational science, the refinement of algorithms, and the year-on-year accumulation of medical big data, it has become an incubator forITBT’s Alignment of Timing, Location, and Human Factors. Shifting drug development from experiment-driven to data-driven models promotes the supply side in delivering high-quality, efficient products—a trend with immense potential.. How to seizeSeizing Industrial Opportunities Amid the ITBT Boom: This Forum Has Invited Representative Innovative Enterprises to Share Case Studies on Innovation Driven by “Favorable Timing, Geographic Advantage, and Human Harmony,” from the Perspectives of Industry Trends, Their Own Products, and Technologies.

(2)Cross-Disciplinary Integration:ITBT Reshapes the Diversified Landscape of Collaborative Industrial Development

New drug development as healthcareThe fastest-growing and most promising market in AI application scenarios, empowered by computational science and IT, can leverage its advantages in algorithms and computing power to facilitate multiple stages of new drug development, accelerating target discovery, compound synthesis, formulation development, crystal structure prediction, and more.. InUnder the leadership and impetus of the ITBT wave, how to achieve advancements in fields such as 3D printing, new drug screening, and synthetic biologyBringing About a Diversified Shift in the Landscape, will also be shared in depth at the forum.

(3)Ecosystem Development:The New Future of the Industry under the Development of ITBT

With the advancement of artificial intelligence technology and the accumulation of medical data resources,An increasing number of new enterprises are entering the ITBT sector, while existing companies are also transforming and upgrading to join the fray. Despite the heated competition, ITBT remains in its early stages in China, with an immature industrial ecosystem. Only when the integration of the IT and BT ecosystems is further enhanced can the biomedical industry enter a new golden age over the next decade, driven by the rise of biological computing. This forum will bring together stakeholders from across the industry chain to discuss current trends and explore a new future built on integrated industrial ecosystems.